Meta-analysis on Successful Ablation After Low- Versus High-Dose Radioiodine Therapy in Patients With Differentiated Thyroid Carcinoma

2016 ◽  
Vol 41 (8) ◽  
pp. 674 ◽  
Author(s):  
Seyed Rasoul Zakavi
Keyword(s):  
Thyroid Carcinoma ◽  
Radioiodine Therapy ◽  
Meta Analysis ◽  
Differentiated Thyroid Carcinoma ◽  
High Dose ◽  
Successful Ablation

scholarly journals Thyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma

2015 ◽  
Vol 17 (1) ◽  
pp. 55-60
Author(s):  
Md Sayedur Rahman Miah ◽  
Md Reajul Islam ◽  
Tanjim Siddika
Keyword(s):  
Thyroid Carcinoma ◽  
Atomic Energy Commission ◽  
Thyroid Volume ◽  
Differentiated Thyroid Carcinoma ◽  
High Dose ◽  
Thyroid Remnant ◽  
Complete Ablation ◽  
Successful Ablation ◽  
Remnant Thyroid ◽  
Radioiodine Ablation

Aims: The aims of the study were to determine the thyroid remnant volume and to see the effect of radioiodine ablation on thyroid remnant volume. Methods: A retrospective analysis of seventy-one differentiated thyroid carcinoma patients treated with high dose radioiodine (I-131) for post surgical ablation of thyroid remnants were done in Institute of Nuclear Medicine & Allied Sciences, Comilla of Bangladesh Atomic Energy Commission. Female were 60 and male were 11 with female-male ration of 5.5:1. All patients enrolled during the period from January 2001 to December 2011. The age range of the patients was 15 years to 90 years. The thyroid remnant volumes were determined by SPECT scintigraphy. High dose radioiodine (I-131) ablations were done with doses ranged from 2.77 GBq (75mCi) to 5.55 GBq (175 mCi). A successful ablation was defined as the absence of activity in the thyroid bed on subsequent imaging studies. Results: Fifty-nine patients (83.1%) showed complete ablation and twelve (16.9%) showed partial ablation of thyroid remnants after radioiodine therapy. The remnant thyroid volume as determined from scintigraphic images was significantly different (p = 0.048) between them who were completely ablated and them who were partially ablated. It was also observed that in complete ablation, 52.5% had thyroid remnant volume <1.0 gm, 40.7% had 1.1 to 2.0 gm, 5.1% had 2.1 to 3.0 gm and 1.7% had > 3.0 gm. i.e., The smaller the volume of thyroid remnant, better the response and larger the volume, the poorer the response to radioiodine. Conclusions: Successful ablation of thyroid remnants significantly depends on their volume and the successful ablation is inversely related with thyroid remnant volume. DOI: http://dx.doi.org/10.3329/bjnm.v17i1.22492 Bangladesh J. Nuclear Med. 17(1): 55-60, January 2014

scholarly journals Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy in Patients with Multinodular Goiters: A Meta-Analysis of Randomized Controlled Trials

2020 ◽  
Vol 52 (12) ◽  
pp. 841-849
Author(s):  
Chunmei Xu ◽  
Ping Wang ◽  
Huikai Miao ◽  
Tianyue Xie ◽  
Xiaojun Zhou ◽  
...  
Keyword(s):  
Fixed Effects ◽  
Dose Group ◽  
Low Dose ◽  
Radioiodine Therapy ◽  
Meta Analysis ◽  
High Dose Group ◽  
High Dose ◽  
Fixed Effects Model ◽  
Recombinant Human Thyrotropin

AbstractA potential reduction of goiter volume (GV) of recombinant human thyrotropin (rhTSH) on multinodular goiters (MNG) was previously reported but controversial. Hence we conducted a meta-analysis to estimate the effect of rhTSH-stimulated radioiodine therapy in patients with MNG. PubMed, Cochrane, CNKI, VIP, and Wanfang databases were searched. Mean difference (MD) and odds ratios with 95% confidence intervals (95% CI) were derived by using an inverse variance random-effects model and fixed-effects model, respectively. Six studies (n=237) were involved in the analysis. For 12 months follow up, high dose (>0.1 mg) of rhTSH significantly reduced GV (MD=17.61; 95% CI=12.17 to 23.04; p<0.00001) compared with placebo. No effective pooled results of low dose of rhTSH (<0.1 mg) were applicable for only one study included. For 6 months follow up, the source of heterogeneity was determined by subgroup and sensitivity analysis. High dose group showed vast improvement in GV reduction (MD=16.62; 95% CI=1.34 to 31.90; p=0.03). The reduction of low dose group compared with placebo was inferior to high dose group. No available data were obtained to assess the influence of rhTSH after 36 months follow up for the only included study. Hypothyroidism incidence was higher for rhTSH group. No publication bias was seen. High dose of rhTSH treatment-stimulated radioactive 131I therapy after 6 months and 12 months follow up had a better effect in reducing GV, but with higher incidence of hypothyroidism. Owing to the limited methodological quality, more clinical researches are warranted in the future.

Sign in / Sign up

Export Citation Format

Share Document